Forskning ved Københavns Universitet - Københavns Universitet


Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme

Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  • Chris J Tyrrell
  • Heather Payne
  • William A See
  • David G McLeod
  • Manfred P Wirth
  • Peter Iversen
  • Jon Armstrong
  • Clive Morris
  • 'Casodex' Early Prostate Cancer Trialists Group
The ongoing Early Prostate Cancer (EPC) programme is assessing bicalutamide ('Casodex') 150 mg, either alone or as adjuvant to treatment of curative intent, in patients with localised or locally advanced prostate cancer (n=8113). This paper presents an exploratory analysis of the subgroup of the EPC programme who received radiotherapy with curative intent (n=1370) in order to determine the efficacy (in terms of progression-free survival [PFS]) and tolerability of bicalutamide 150 mg in this setting.
TidsskriftRadiotherapy & Oncology
Udgave nummer1
Sider (fra-til)4-10
Antal sider7
StatusUdgivet - 1 jul. 2005

ID: 34081251